FDA Clearance Tracker · P100034-S032
Optune
Last checked: Nov 20, 2026Latest source record: Feb 2, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Feb 2, 2024
Approved
Time to decision
192 days
Received Jul 25, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P100034-S032
- Device name
- Optune
- Applicant
- Novocure, GmbH
- Applicant location
- Baar
- Received
- Jul 25, 2023
- Decided
- Feb 2, 2024
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P100034
Device type
- Device class
- Class III
- Specialty
- Neurology & Neurosurgery
FDA's approval statement
As written in FDA's record.
approval for a manufacturing site located at United States (U.S.) Operation Center II (USOC II), Novocure Inc., 2555 USA Parkway, Suite 104A, Sparks, Nevada 89437, that will perform the activities of receipt, cleaning, acceptance, storage, service, packaging, labeling and release for distribution of the Optune treatment kit.
Source documents
Other decisions for Novocure, GmbH
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Optune PaxBreakthroughPMA
P250034 · Decided Feb 11, 2026 · 180 days after receipt
Device type: Low Electric Field Generator for Pancreatic Cancer Treatment (SHC) · General & Plastic Surgery
- Optune LuaPMA
P230042 · Decided Oct 15, 2024 · 305 days after receipt
Device type: Electrical tumor treatment fields for non-small cell lung cancer (SDA) · Anesthesiology & Respiratory
- OPTUNE (FORMERLY THE NOVOTTF-100A SYSTEM)PMA supplement
P100034-S013 · Decided Oct 5, 2015 · 178 days after receipt · Panel Track
Device type: Stimulator, low electric field, tumor treatment (NZK) · Neurology & Neurosurgery
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.